Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528314 | 0.84 | GABRA1 (0.41) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL22587363 | 0.82 | ADRA2A (0.49) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL28344739 | 0.79 | TRPA1 (0.33) | TRPA1ALDH1A1TSHROPRM1OPRL1 | |
| SCHEMBL16050167 | 0.79 | AKR1B1 (0.43) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL14619519 | 0.77 | TRPA1 (0.34) | TRPA1ALDH1A1TSHROPRM1OPRL1 | |
| SCHEMBL2535263 | 0.77 | KIF11 (0.42) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL5487704 | 0.75 | GABRB3 (0.41) | GABRB3GABRA1GABRG2 | |
| SCHEMBL586923 | 0.74 | ADRA2A (0.43) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL2525541 | 0.74 | ADRA2A (0.47) | ADRA2AGABRB3GABRA1GABRG2GABRB2 | |
| SCHEMBL3724536 | 0.74 | ADRA2A (0.43) | ADRA2AGABRB3GABRA1GABRG2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005936-B2 | Photoactive bioadhesive compositions | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-06-26 | — | — | US | claimed |
| US-20150315434-A1 | New Photoactive Bioadhesive Compositions | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-11-05 | — | — | US | claimed |
| WO-2014081391-A1 | NEW PHOTOACTIVE BIOADHESIVE COMPOSITIONS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-05-30 | — | — | WO | claimed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-10005936-B2 | Photoactive bioadhesive compositions | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-06-26 | — | — | US | disclosed |
| US-20150315434-A1 | New Photoactive Bioadhesive Compositions | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-11-05 | — | — | US | disclosed |
| WO-2014081391-A1 | NEW PHOTOACTIVE BIOADHESIVE COMPOSITIONS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-05-30 | — | — | WO | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1749011-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157447-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | NAIDU B N | 2006-12-07 | — | — | US | disclosed |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2005118593-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005936-B2 | Photoactive bioadhesive compositions | L1CAM, CDH1, PCNA | ADRA2A 1906/4885GABRB3 524/4885GABRA1 158/4885 |
| US-20060199956-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ADRA2A 4041/4885GABRB3 2723/4885GABRA1 1911/4885 |
| US-20060276466-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ADRA2A 4041/4885GABRB3 2723/4885GABRA1 1911/4885 |
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | ADRA2A 4794/4885GABRB3 4806/4885GABRA1 4736/4885 |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | ADRA2A 4041/4885GABRB3 2723/4885GABRA1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.